CD8 + T cells in chronic viral infections such as HIV develop functional defects including loss of interleukin-2 (IL-2) secretion and decreased proliferative potential that are collectively termed 'exhaustion' 1 . Exhausted T cells express increased amounts of multiple inhibitory receptors, such as programmed death-1 (PD-1) 2, 3 , that contribute to impaired virus-specific T cell function. Although reversing PD-1 inhibition is therefore an attractive therapeutic strategy, the cellular mechanisms by which PD-1 ligation results in T cell inhibition are not fully understood. PD-1 is thought to limit T cell activation by attenuating T cell receptor (TCR) signaling 4, 5 . It is not known whether PD-1 also acts by upregulating genes in exhausted T cells that impair their function. Here we analyzed gene expression profiles from HIV-specific CD8 + T cells in individuals with HIV and show that PD-1 coordinately upregulates a program of genes in exhausted CD8 + T cells from humans and mice. This program includes upregulation of basic leucine transcription factor, ATF-like (BATF), a transcription factor in the AP-1 family. Enforced expression of BATF was sufficient to impair T cell proliferation and cytokine secretion, whereas BATF knockdown reduced PD-1 inhibition. Silencing BATF in T cells from individuals with chronic viremia rescued HIV-specific T cell function. Thus, inhibitory receptors can cause T cell exhaustion by upregulating genes-such as BATF-that inhibit T cell function. Such genes may provide new therapeutic opportunities to improve T cell immunity to HIV.
We hypothesized that inhibitory receptors such as PD-1 function to inhibit T cells not only by reducing TCR signaling but also by inducing the expression of genes that impair T cell function. To test this hypothesis, we analyzed gene expression profiles from HIVspecific CD8 + T cells for upregulation of PD-1-induced genes.
The majority of individuals infected with HIV show chronic elevation of viral load in the absence of antiretroviral therapy (progressors), which is associated with defects in HIV-specific T cell cytokine secretion, proliferation and survival 6, 7 . In contrast, spontaneous control of viral replication has been documented for a small minority of individuals (controllers) 8 . Analysis of CD8 + T cell responses to HIV in progressors and controllers therefore allows a comparison of populations of human antigen-specific T cells at the extremes of functional competence.
We sorted CD8 + T cells specific for epitopes from the Gag protein (hereafter termed HIV-specific CD8 + T cells) from 18 progressors and 24 controllers (Fig. 1a, Supplementary Fig. 1 and Supplementary Table 1 ). The gene expression profiles of HIV-specific CD8 + T cells from progressors showed marked differences compared to those from controllers (n = 518 genes, moderated t statistic <-2.0, Fig. 1b and Supplementary Table 2) . Genes upregulated in HIV-specific CD8 + T cells from progressors were enriched for those involved with the interferon response and major histocompatibility complex expression (Supplementary Table 3) , consistent with a higher viral load in progressors. HIV-specific CD8 + T cells from controllers were enriched for genes involved in mRNA transcription and protein translation, consistent with previous observations of defects seen in the mouse model of chronic lymphocytic choriomeningitis virus (LCMV) infection 9 (Supplementary Table 4) . We therefore compared the expression profiles of HIV-specific CD8 + T cells to exhausted LCMV-specific CD8 + T cells from the mouse model 9 . Using an analytic technique called gene set enrichment analysis [10] [11] [12] (Supplementary Methods), we analyzed the expression profiles of mouse virus-specific CD8 + T cells during infection with each of Transcriptional analysis of HIV-specific CD8 + T cells shows that PD-1 inhibits T cell function by upregulating BATF 1 1 4 8 VOLUME 16 | NUMBER 10 | OCTOBER 2010 nature medicine two strains of LCMV: clone 13 (Cl13), which gives rise to chronic infection with T cell exhaustion, and Armstrong (Arm), an acute infection that does not cause T cell exhaustion 9, 13 . We found that the HIV progressor signature was significantly enriched in the profiles of exhausted LCMV-specific CD8 + T cells from Cl13 infection (P = 4.8 × 10 −5 , Supplementary Fig. 2 ), suggesting a global similarity between the transcriptional profiles of exhausted CD8 + T cells in humans and in the mouse model. We next asked whether this exhausted CD8 + T cell signature was influenced by PD-1 signaling. To determine this, we first identified the genes upregulated after PD-1 ligation. We incubated PD-1-expressing Jurkat cells with beads coated with a cross-linking antibody to PD-1 together with antibodies to CD3 and CD28 (PD-1-CD3-CD28 beads); or with beads coated with equivalent amounts of control antibody together with CD3 and CD28 (CD3-CD28 beads). Incubation with PD-1-CD3-CD28 beads resulted in significantly decreased production of IL-2 compared to cells incubated with CD3-CD28 beads (P = 0.007, Fig. 1c) , as previously observed 14, 15 . Microarray analysis identified over 1,000 genes that were significantly upregulated in cells functionally inhibited by PD-1 (n = 1179, t > 2.0, Fig. 1d and Supplementary Table 5 ). A similar number of genes had reduced expression after PD-1 ligation (n = 1,361, t < −2.0, Fig. 1d and Supplementary Table 5 ). We validated 13 representative genes that were upregulated in PD-1-ligated Jurkat cells. Incubation of human CD4 + T cells with PD-1 ligand-immunoglobulin fusion protein (PD-L1-Ig)-CD3-CD28 beads led to the coordinate upregulation of these representative PD-1 signature genes in a PDL1-Ig dosedependent manner (Supplementary Fig. 3) . Thus, ligation of PD-1 in CD3-and CD28-stimulated cells induces a specific transcriptional program in both Jurkat cells and primary human T cells.
We sought to determine whether the transcriptional program induced by PD-1 signaling defined in vitro could be detected in gene expression profiles from exhausted CD8 + T cells ex vivo. We therefore tested whether PD-1-induced genes were coordinately upregulated in HIV-specific CD8 + T cells from HIV progressors. By enrichment analysis, we found that a set of PD-1 signature genes was significantly upregulated in the HIV progressors compared with controllers (P = 5 × 10 −6 , Fig. 1e) . Similarly, we found that PD-1 signature genes were significantly upregulated in exhausted LCMV-specific CD8 + T cells from Cl13 infection compared with Arm infection (P = 2 × 10 −4 , Supplementary Fig. 4 ). Thus PD-1 ligation results in upregulation of a consistent pattern of genes in exhausted CD8 + T cells in humans and mice.
The upregulation of PD-1 signature genes in exhausted CD8 + T cells contrasted with that seen in profiles of human virus-specific CD8 + T cells associated with functional T cell responses. Using single-sample gene set enrichment analysis (Supplementary Methods), we found that the PD-1 signature was significantly more enriched in HIV-specific CD8 + T cells than in antigen-specific CD8 + T cells specific for cytomegalovirus (CMV) (P < 0.01), Epstein-Barr virus (EBV) (P < 0.001) or influenza virus (P < 0.001) from healthy HIV-uninfected donors (Fig. 1f) . Notably, the PD-1 signature was significantly more enriched in HIV-specific T cells than in EBVspecific T cells, despite the fact EBV-specific T cells express PD-1 (refs. 16,17) . This suggests that the upregulation of PD-1 signature genes may not occur in all cells that express PD-1 but may reflect increased strength and duration of PD-1 signaling experienced by CD8 + T cells in the setting of chronic infection. We reasoned that genes upregulated by PD-1 in exhausted CD8 + T cells might include those involved in the inhibition of T cell function. To refine the list of candidate genes, we identified genes that were both upregulated by PD-1 ligation in Jurkat cells and upregulated in HIV progressors ( Fig. 2a and Supplementary Table 6 ). We focused on transcription factors because of their broad effect on the cell state. Of the 75 genes common to both gene sets, only three encoded transcription factors: BATF, signal transducer and activator of transcription-1 (STAT1) and interferon regulatory factor-9 (IRF9) ( Fig. 2a and Supplementary Table 6 ). We selected BATF for further analysis because it has been shown to function as a negative regulator of AP-1 activity 18, 19 . Moreover, we have previously observed it to be upregulated during CD8 + memory differentiation in humans and mice 20 , suggesting that it may have a conserved role in regulating T cell function. BATF expression showed a two-to threefold increase in both primary human CD4 + and CD8 + T cells after incubation with PD-L1-Ig-CD3-CD28 beads compared with CD3-CD28 beads, indicating that BATF expression is increased by PD-1 ligation in vitro (P = 0.001 and P = 0.02, respectively, Fig. 2b) .
We observed high BATF levels in antigen-specific T cells with the greatest degree of dysfunction (Fig. 2c,d ). BATF expression measured by microarray was significantly higher in exhausted HIV-specific CD8 + T cells from progressors than in HIV-specific T cells from controllers (P = 0.003, Fig. 2c ). However, BATF expression was not significantly different in naive CD8 + T cells from controllers or progressors (Fig. 2c) . A significant correlation existed between microarray and RT-PCR measurements of BATF expression (r = 0.53, P = 0.02, Spearman's rank test, Supplementary Fig. 5) .
To define the kinetics of Batf expression after infection with a persistent virus, we compared Batf expression in mouse virusspecific CD8 + T cells during acute and chronic LCMV infection (Fig. 2d) . As early as day 8 after infection, epitope GP33 (DbGP33)-specific CD8 + T cells in LCMV Cl13 infection expressed significantly higher amounts of Batf than in Arm infection (P = 0.02). Batf expression was maintained at higher levels in virusspecific cells in Cl13 infection at day 15 and by day 30 was approximately sevenfold higher than in DbGP33-specific CD8 + T cells generated during Arm infection (P = 0.02). The higher expression of Batf during chronic versus acute infection was coincident with the upregulation of PD-1, as GP33-specific T cells in Cl13 infection showed increased levels of both PD-1 and Batf by day 8 (Fig. 2d,e) . Increased Batf expression is therefore an early and persistent feature of exhausted CD8 + T cells in the setting of chronic viral infection in vivo and temporally correlates with upregulation of PD-1.
We next tested whether BATF could inhibit T cell function. Fig. 6a ) markedly reduced proliferation in response to CD3-CD28 beads compared to vector-transduced cells (P = 0.002, Fig. 3a,b) . Apoptosis was also slightly increased in BATF-overexpressing cells after stimulation (29% versus 20%, P = 0.013, Fig. 3a,b) , consistent with the previously defined role of PD-1 signaling in reducing cell survival 21 . However, the majority of BATF-overexpressing cells were viable, suggesting that reduced proliferation was not simply from cell death. Overexpression of BATF also significantly reduced IL-2 secretion after CD3 and CD28 stimulation, (P = 4.5 × 10 −5 ) but was not overtly toxic, because interferon-γ (IFN-γ) secretion was not significantly reduced compared with vector controls (Fig. 3c) . Thus, increased expression of BATF reduces proliferation and IL-2 secretion in primary human T cells.
Overexpression of BATF in primary human T cells (Supplementary
Enforced expression of BATF in vitro did not increase the expression of PD-1 or of two other inhibitory receptors (CD244 or CD160) in CD8 + or CD4 + T cells (Supplementary Fig. 6b-e) . This suggests that BATF does not mediate inhibition by modulating the expression of these inhibitory receptors. Future studies will be required to determine whether BATF regulates other components of the PD-1-induced expression signature.
We next asked whether depletion of BATF enhances T cell function by using shRNA-mediated gene silencing (Fig. 3d,e) . Compared with control hairpins, depletion of BATF in Jurkat cells with two different shRNA sequences (Fig. 3d) significantly increased IL2 expression in cells cultured with PD-1-CD3-CD28 beads (P < 0.01, Fig. 3e) , reversing the IL-2 inhibition to levels seen in cells stimulated with CD3-CD28 beads. Testing of additional hairpin sequences showed that there was a strong correlation between the extent of knockdown and the degree of increase in IL-2 secretion, confirming the on-target specificity of BATF silencing (r = −0.82, P = 0.056, Spearman's rank test; Fig. 3f) . BATF silencing also increased IL-2 expression in cells stimulated with CD3-CD28 beads without exogenous PD-1 cross-linking (P < 0.01, Fig. 3e ), suggesting that pathways in addition to the PD-1 pathway can inhibit cell activation via BATF. Silencing BATF may therefore have the effect of increasing IL-2 expression not only by relieving PD-1-mediated inhibition but also by impairing other negative feedback pathways. Consistent with this, the expression of BATF across 42 samples of HIV-specific CD8 + T cells significantly correlated with expression of several receptors with known or putative inhibitory function (Supplementary Fig. 7 ) 22, 23 .
Finally, we tested whether silencing BATF would improve the function of HIV-specific T cells. We assessed HIV-specific T cell function after BATF knockdown (Fig. 4a,b) by measuring cytokine secretion or proliferation in response to Gag peptides. BATF knockdown caused a significant increase in CD8 + Gag-specific IFN-γ secretion (Fig. 4c) compared to a control siRNA pool, increasing IFN-γ secretion by an average of 60% (P < 0.0001). We observed similar results in HIVspecific CD4 + T cells, where silencing BATF caused a twofold increase in Gag-specific IL-2 secretion (P = 0.008, Fig. 4d ) and a trend toward an increase in IFN-γ secretion (P = 0.078, Fig. 4e ). HIV-specific CD8 + T cell proliferation was also increased by BATF knockdown, with a fivefold increase in the fraction of proliferating cells incubated with Gag peptides (P = 0.004, Fig. 4f ). Reducing BATF expression therefore increases the function of exhausted HIV-specific T cells. We show that exhausted T cells specific for HIV in humans and for LCMV in mice share a common expression signature that reflects the transcriptional consequences of PD-1 receptor ligation. Our data therefore suggest a model in which inhibitory receptors such as PD-1 may mediate T cell exhaustion not only by limiting TCR signaling but also by inducing the expression of proteins such as BATF that inhibit T cell function.
BATF is a highly conserved member of the AP-1 family, a group of transcription factors that regulate many aspects of cellular function in the immune system 24 . Recent studies show that BATF is required for T helper type 17 and follicular T helper cell differentiation 25, 26 . BATF may therefore be one of a number of transcription factors, such as B lymphocyte-induced maturation protein-1 (refs. 27,28) , that have distinct, context-dependent roles both in regulating the function of T cells responding to chronic viral infection and in CD4 + lineage decisions. Our studies do not identify the mechanism by which PD-1 ligation induces BATF upregulation, or whether this happens by direct or indirect pathways. However, our findings give impetus to further studies of how BATF regulates T cell state.
Blockade of PD-1-PDL-1 interactions partially reverses T cell dysfunction 16, 17 and improves control of viral replication 2, 29 , indicating that the function of exhausted T cells can be rescued even in settings of viral persistence. BATF and the pathways that control its activity may provide new opportunities to reverse CD8 + T cell exhaustion. These findings suggest that integrated genomic analysis of T cell responses in humans can be used to identify new regulators of T cell function that are potential therapeutic targets for improving T cell immunity in chronic infection.
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Subjects. Subjects were recruited from outpatient clinics at local Boston hospitals, or referred from providers throughout the US, following institutional review board approval (Partners Institutional Review Board ) and with written informed consent. HIV controllers included elite controllers (n = 20) with HIV RNA below the level of detection for the respective available ultrasensitive assay (<75 copies per ml by DNA or <50 copies per ml by ultrasensitive PCR); and viremic controllers (n = 4) with HIV RNA levels <2,000 copies per ml. Chronic progressors (n = 18) were defined as having HIV RNA levels above 2,000 copies (Supplementary Table 1 ). All subjects were off therapy and had detectable HIV-specific CD8 + T cells in the peripheral blood, allowing a median of 21,500 HIV Gag tetramer + T cells (range 3,00 −85,000 cells) to be isolated for microarray analysis from each subject.
Flow cytometry and sorting. PBMCs were isolated by density centrifugation and were stained with a cocktail of antibodies to exclude irrelevant lineages (CD4, clone 13B8.2, Beckman Coulter; CD14, RMO52, Beckman Coulter; CD19, J3-119, Beckman Coulter; CD56, NCAM16.2, BD Biosciences) and dead cells (annexin V, BD Biosciences), antibody to CD8 (clone SFCI21Thy2D3, Beckman Coulter) and major histocompatibility complex class I HIV Gagspecific tetramers (generated in the Walker laboratory) to identify the antigenspecific populations, and antibodies against CD62L (clone DREG56, Beckman Coulter) and CD45RA (clone 2H4LDH11LDB9, Beckman Coulter) for memory phenotype characterization of the tetramer-positive fraction. CD8 + tetramer + cells were sorted with a FACSAria Cell Sorter (BD Biosciences). All experiments examining proliferation via CFSE dilution and survival via annexin V (BD Biosciences) staining were collected on a FC500 flow cytometer (Beckman Coulter). Analysis of flow cytometry data was carried out with FlowJo software (version 8.8.6, Tree Star).
Microarray data acquisition and analysis. Tetramer-sorted human CD8 + T cells or Jurkat cells after 18 h of bead stimulation were pelleted and resuspended in TRIzol (Invitrogen). RNA was extracted with the RNAdvance Tissue Isolation kit (Agencourt). Concentrations of total RNA were determined with a Nanodrop spectrophotometer or Ribogreen RNA quantification kit (Molecular Probes/Invitrogen). RNA purity was determined by Bioanalyzer 2100 traces (Agilent Technologies). Total RNA was amplified with the WT-Ovation Pico RNA Amplification system (NuGEN) according to the manufacturer's instructions. After fragmentation and biotinylation, cDNA was hybridized to Affymetrix HT HG-U133A or HG-U133A2.0 microarrays. Microarray data for CMV-, EBV-and influenza-specific CD8 + T cells and for LCMV-specific T cells were obtained from previous studies 9, 20 . A detailed description of the microarray data analysis can be found in the Supplementary Methods. Quantitative PCR. Expression of BATF after in vitro stimulation of primary human T cells, shRNA and overexpression experiments was determined by real-time quantitative PCR with Taqman gene expression assays for BATF (assay Hs00232390_m1) and β-actin (Hs00357333_g1), which served as a loading and normalization control. For LCMV mouse experiments, RNA was converted to cDNA with a high-capacity cDNA kit, and quantitative RT-PCR was performed with Taqman assay kits (Batf, Gapdh, Hprt1; Applied Biosystems). Expression levels were compared with the relative quantification method, comparing Batf expression to either Gapdh or Hprt1 housekeeping genes. Quantitative multiplex RT-PCR via ligation-mediated amplification was carried out as previously described 30 . PD-1 signature genes were selected for the multiplex validation panel based on previously established criteria 30 , and sequences for primer sets are available upon request.
Mouse model of LCMV infection. Four-week-old C57BL/6 mice were purchased from Jackson Laboratory and were used in accordance with the Wistar Institute Institutional Animal Care and Use Committee guidelines. Mice were infected with 2 × 10 5 plaque-forming units of LCMV Arm intraperitoneally or 2 × 10 6 plaque-forming units LCMV Cl13 intravenously as previously described 13 . Viruses were grown and titered as previously described 13 . Groups of mice were infected with either LCMV Arm or LCMV cl13. At 8, 15 or 30 d after infection, spleens were collected and splenocytes pooled before CD19 depletion and sorting. LCMV tetramer-specific (DbGP33) CD8 + T cells were sorted by a BD FACSAria directly into siliconized 1.5-ml tubes containing Trizol LS, followed by RNA extraction. Separate aliquots of cells were stained for PD-1 expression as described previously 9 .
BATF small interfering RNA knockdown in HIV samples. PBMCs from untreated, chronically HIV-infected individuals were isolated by densitygradient centrifugation. Inhibition of BATF expression was achieved through siRNA transfection by electroporation on a Gene Pulser XCell (BioRad). Fifteen million cells were resuspended in 300 μl of Opti-MEM in a 2-mm cuvette and pulsed with 1 nmol of siRNA (ON-TARGET Non-Targeting pool or BATF ON-TARGETplus SMARTpool, Dharmacon). Pulse conditions were designed to maximize electroporation efficiency in T cells (a unique square wave with a pulse of 360 V and a duration of 5 ms), and transfection efficiency was assayed with siGlo fluorescent oligonucleotides (Dharmacon). For assessment of CD4 + T cell cytokine responses, CD8 + T cell-depleted PBMCs (RosetteSep CD8 + depletion reagents; StemCell) were stimulated with an HIV Gag peptide pool (1 μg ml −1 per peptide) or left unstimulated. For HIV-specific CD8 + T cell cytokine responses, nondepleted PBMCs were stimulated with 0.2 μg ml −1 of HIV optimal epitopes (Peptide Core Facility, Massachusetts General Hospital). After a 96-h incubation, IFN-γ and IL-2 levels were measured. Proliferation of CD8 + T cells was measured 6 d after transfection and stimulation by a CFSE assay as published before 18 .
Additional methods. Detailed methodology is described in the Supplementary Methods. 
